B.S. in Life Science, Peking University;
Ph.D. in Neuroscience, University of British Columbia;
Previous Postdoctoral fellow of Neurology and ICE, Johns Hopkins University;
Dr. Fan has been elected as one of the' 30 Global Innovative talents of Chinese entrepreneurs' in 2018;
17 years of research experience in stroke and neurodegenerative disease models and mechanisms. 10 years of experience in pluripotent stem cell culture, iPSC reprogramming and neural differentiation. Since 2017, Dr. Fan has led the Hopstem team and together established the company's IPs and iPSC cell product R&D platform.
Peking University Health Science Center, Master of Medicine;
Rensselaer Polytechnic Institute, USA, Ph.D.;
Albany Medical Center, USA, Postdoc;
University of Washington, USA, Instructor;
Hangzhou Future Sci & Tech City Overseas High-level Talent. 2018;
As the outstanding figure in Hangzhou’s Academician Station, highlighted in Hangzhou Youth Newspaper. 2019;
Core member of Leading Innovation Team Award by Zhejiang Province. 2020;
Leader of Outstanding Team Award of Huadong Medicine. 2020;
Served as Medical director in Hangzhou Adamerck, Head of Clinical Medicine and Medical Affairs department in Huadong Medicine. In charge of the clinical development of multiple projects from IND to NDA, as well as project leaders for multiple licensed-in projects.
Former SVP of AbPro;
Founder and CEO of Jemincare Therapeutics;
VP of BD of HD Bioscience;
Sr.Director of BD of WuXiAppTec.25 years of research;
BD and management experience in pharmaceutical companies.
More than 16 years of experience in human resources management in pharmaceutical companies;
Worked for CR Sanjiu Medical & Pharmaceutical and Ruiquan Health;
Head of HR and administration department.?
Ph.D. in Biophysics, University of Chinese Academy of Sciences;
Previous Research Associate (Postdoc), University of Wisconsin-Madison;
Experienced with iPSC/ESC culture and glia / neural differentiation. Dr. Wang has completed high-content and high-throughput screening of human glial cells and neurons derived from iPSC from Rett Syndrome patients at UWM. He leads the Hopstem R&D team to develop innovative iPSC cell products.
Ph.D. and postdoctoral fellow in Chemistry-Biomaterials, Technical University of Berlin;
More than 10 years of experience in stem cell nanomaterials and cytotoxicity study;
Responsible for clinical product development in Hopstem.
Ph.D. in neuroscience, School of medicine, Zhejiang University;
More than 10 years of training in Neuroscience, Cell Biology, and CRISPR gene editing;
Responsible for QC method development and technical supportin Hopstem.
Master’s Degree of Nanjing University of Chinese Medicine;
25 years of experience in pharmaceutical registration, including First-in-Class new drugs, cell therapy products, and experience for China/US IND application;
Worked for Simcere Pharmaceutical, Nanjing King-Friend and MITRO Biotech;
Responsible for domestic/overseas registration in Hopstem.
Fellow of the US National Academy of Medicine;
Director of the Institute for Cell Engineering,
Director, Morris K. Udall Parkinson's Disease Research Center,
Leonard and Madlyn Abramson Professor in Neurodegenerative Diseases,
Professor of Neurology, Neuroscience and Pharmacology and Molecular Sciences,
Johns Hopkins University;
Internationally renowned scientist in Parkinson's and CNS diseases;
Dr. Ted Dawson has received funding support of more than 76 million US dollars from the United States National Institutes of Health and other foundations, has published 445 top academic articles, with an H index of 145, and a total of more than 85,000 citations.
Professor of Neurology, Neuroscience and Physiology, Johns Hopkins University;
Director of Neuroregeneration and Stem Cell Program, Institute of Cell Engineering,
Johns Hopkins University;
Internationally renowned scientist in neuronal cell death and protection, stroke and neurodegenerative diseases;
Dr. Valina Dawson has received funding support of more than 60 million US dollars from NIH and other foundations, and has published more than 221 top academic articles, with an H index of 123, and total citations of 63,689.
Fellow of the Academy of Science of the Royal Society of Canada;
Internationally renowned neuroscientist in stroke and other CNS disorders; HHMI investigator;
Professor, Brain Research Center, University of British Columbia, Canada;
Chairman of Stroke Research Association of British Columbia and Yukon, Canada;
Dean of the School of Life and Health, Shenzhen University of Science and Technology.
Ph.D. in Molecular Medicine from Kyoto University, School of Medicine, Japan;
Founder of BLA Regulatory;
Former Director of Regulatory Affairs of AstraZeneca;
More than 15 years of experience in Biopharmaceutical industry;
President of Chinese Biopharmaceutical association (CBA,2018-2019).